Skip to content
Clinical Trials – home
GreeceBack to Greece

Clinical trials in Kalamaria – page 4

740 clinical trials in Kalamaria, Greece. Every trial is listed in the EU Clinical Trials Register and updated daily.

GreeceOur site in GreeceΚλινικεσΔοκιμεσ.gr(opens in a new tab)
Kalamaria at a glance
740
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

740 trials in Kalamaria

Open in trial search

Study of Elafibranor for Adults with Primary Biliary Cholangitis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Elafibranor
  • Sponsor:Ipsen Bioscience Inc.

Study of Dostarlimab After Chemoradiation for Adults with Advanced Unresected Head and Neck Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Clazakizumab for Heart Disease in Adults with End-Stage Kidney Disease on Dialysis

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Clazakizumab
  • Sponsor:CSL Behring LLC

Hepatic cirrhosis+2

Recruiting

Study on Efruxifermin for Patients with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) or Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Efruxifermin
  • Sponsor:Akero Therapeutics Inc.

Glaucoma+1

Recruiting

A study comparing the effectiveness of brimonidine tartrate and timolol eye drops versus a standard combination in patients with glaucoma or ocular hypertension

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:OmniVision GmbH

Cardiac failure

Recruiting

Study on the Effects and Safety of Finerenone for Patients with Heart Failure Who Cannot Use Steroidal Mineralocorticoid Receptor Antagonists

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Study of Rilvegostomig or Pembrolizumab for First-line Treatment in Patients with PD-L1-high Metastatic Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:AstraZeneca AB

Study on the Long-Term Safety of Belimumab for Adults with Systemic Sclerosis-Related Lung Disease

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Belimumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Neutropenia

Recruiting

Study on Mavorixafor for Patients with Chronic Neutropenia Experiencing Recurrent or Serious Infections

Investigational
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mavorixafor
  • Sponsor:X4 Pharmaceuticals Inc.

Cardiac failure

Recruiting

Study on the Effects of Finerenone in Patients with Heart Failure and Preserved Ejection Fraction Hospitalized for Acute Decompensated Heart Failure

Investigational
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Finerenone
  • Sponsor:Colorado Prevention Center

Other cities in Greece

The busiest research cities in the country

All 48 cities in Greece

Clinical research in Kalamaria

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on atherosclerotic cardiovascular disease in patients with end-stage kidney disease are being conducted. The research aims to evaluate novel therapeutic approaches for patients undergoing dialysis treatment.

  • Cardiovascular Outcomes
  • Inflammatory Biomarkers
  • Dialysis Patient Care

These studies specifically examine the effectiveness of targeted treatments in reducing C-reactive protein levels, a key marker of inflammation in cardiovascular disease among dialysis patients.

02 Nephrology Studies

Current research explores the intersection of kidney disease and cardiovascular complications, with a particular focus on patients receiving maintenance dialysis treatment.

  • End-Stage Kidney Disease Management
  • Cardiovascular Risk Assessment
  • Treatment Response Monitoring

The trials investigate intravenous therapeutic options designed to improve outcomes for patients with complex cardiovascular and renal conditions.

03 Inflammatory Disease Research

Specialized studies are evaluating the role of inflammation markers in cardiovascular complications among dialysis patients, testing innovative therapeutic approaches.

  • Inflammatory Biomarker Analysis
  • Disease Progression Monitoring
  • Treatment Response Assessment

This research aims to advance our understanding of inflammation's role in cardiovascular disease among patients with kidney failure.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.